New research by scholars at the University of Pittsburgh
shows how much better access American patients have to new cancer medicines
than their peers in other developed countries:
Of 45 anticancer drug indications
approved in the United States between January 1, 2009, and December 31, 2013,
64% (29) were approved by the European Medicines Agency; 76% (34) were approved
in Canada; and 71% (32) were approved in Australia between January 1, 2009, and
June 30, 2014. The U.S. Medicare program covered all 45 drug indications; the
United Kingdom covered 72% (21) of those approved in Europe— only 47% (21) of
the drug indications covered by Medicare. Canada and France covered 33% (15)
and 42% (19) of the drug indications covered by Medicare, respectively, and
Australia was the most restrictive country, covering only 31% (14).
(Y. Zhang, et al., “Comparing the Approval and Coverage Decisions of New
Oncology Drugs in the United States and Other Selected Countries,” Journal of Managed Care and Specialty
Pharmacy, 2017 Feb;23(2):247-254.

